YC Companies/Summer 2021/Catena Biosciences
Catena Biosciences logo

Catena Biosciences

Using protein coupling to build new therapies

Summer 2021Healthcare / Healthcare -> TherapeuticsBerkeley, CA, USA7 employees
Biotech
Therapeutics

About

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.

Build your own investing agent

GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.

Join the GPAgent waitlist

Founders (2)

Marco Lobba
Founder
Matthew Francis
Founder

Details

Status
Active
Stage
Early
Team Size
7
Regions
United States of America, America / Canada, Remote, Partly Remote